Cargando…
Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444663/ https://www.ncbi.nlm.nih.gov/pubmed/37432417 http://dx.doi.org/10.1007/s00277-023-05321-3 |
| _version_ | 1785093998755446784 |
|---|---|
| author | Nowakowski, Grzegorz S. Yoon, Dok Hyun Mondello, Patrizia Joffe, Erel Peters, Anthea Fleury, Isabelle Greil, Richard Ku, Matthew Marks, Reinhard Kim, Kibum Zinzani, Pier Luigi Trotman, Judith Sabatelli, Lorenzo Waltl, Eva E. Winderlich, Mark Sporchia, Andrea Kurukulasuriya, Nuwan C. Cordoba, Raul Hess, Georg Salles, Gilles |
| author_facet | Nowakowski, Grzegorz S. Yoon, Dok Hyun Mondello, Patrizia Joffe, Erel Peters, Anthea Fleury, Isabelle Greil, Richard Ku, Matthew Marks, Reinhard Kim, Kibum Zinzani, Pier Luigi Trotman, Judith Sabatelli, Lorenzo Waltl, Eva E. Winderlich, Mark Sporchia, Andrea Kurukulasuriya, Nuwan C. Cordoba, Raul Hess, Georg Salles, Gilles |
| author_sort | Nowakowski, Grzegorz S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10444663 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104446632023-08-24 Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma Nowakowski, Grzegorz S. Yoon, Dok Hyun Mondello, Patrizia Joffe, Erel Peters, Anthea Fleury, Isabelle Greil, Richard Ku, Matthew Marks, Reinhard Kim, Kibum Zinzani, Pier Luigi Trotman, Judith Sabatelli, Lorenzo Waltl, Eva E. Winderlich, Mark Sporchia, Andrea Kurukulasuriya, Nuwan C. Cordoba, Raul Hess, Georg Salles, Gilles Ann Hematol Correction Springer Berlin Heidelberg 2023-07-11 2023 /pmc/articles/PMC10444663/ /pubmed/37432417 http://dx.doi.org/10.1007/s00277-023-05321-3 Text en © Springer-Verlag GmbH Germany, part of Springer Nature 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Nowakowski, Grzegorz S. Yoon, Dok Hyun Mondello, Patrizia Joffe, Erel Peters, Anthea Fleury, Isabelle Greil, Richard Ku, Matthew Marks, Reinhard Kim, Kibum Zinzani, Pier Luigi Trotman, Judith Sabatelli, Lorenzo Waltl, Eva E. Winderlich, Mark Sporchia, Andrea Kurukulasuriya, Nuwan C. Cordoba, Raul Hess, Georg Salles, Gilles Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma |
| title | Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma |
| title_full | Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma |
| title_fullStr | Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma |
| title_full_unstemmed | Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma |
| title_short | Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma |
| title_sort | correction to: re‑mind2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑br), car‑t therapies, and lenalidomide/rituximab (r2) based on real‑world data in patients with relapsed/refractory diffuse large b‑cell lymphoma |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444663/ https://www.ncbi.nlm.nih.gov/pubmed/37432417 http://dx.doi.org/10.1007/s00277-023-05321-3 |
| work_keys_str_mv | AT nowakowskigrzegorzs correctiontoremind2comparativeeffectivenessoftafasitamabpluslenalidomideversuspolatuzumabvedotinbendamustinerituximabpolabrcarttherapiesandlenalidomiderituximabr2basedonrealworlddatainpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT yoondokhyun correctiontoremind2comparativeeffectivenessoftafasitamabpluslenalidomideversuspolatuzumabvedotinbendamustinerituximabpolabrcarttherapiesandlenalidomiderituximabr2basedonrealworlddatainpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT mondellopatrizia correctiontoremind2comparativeeffectivenessoftafasitamabpluslenalidomideversuspolatuzumabvedotinbendamustinerituximabpolabrcarttherapiesandlenalidomiderituximabr2basedonrealworlddatainpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT joffeerel correctiontoremind2comparativeeffectivenessoftafasitamabpluslenalidomideversuspolatuzumabvedotinbendamustinerituximabpolabrcarttherapiesandlenalidomiderituximabr2basedonrealworlddatainpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT petersanthea correctiontoremind2comparativeeffectivenessoftafasitamabpluslenalidomideversuspolatuzumabvedotinbendamustinerituximabpolabrcarttherapiesandlenalidomiderituximabr2basedonrealworlddatainpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT fleuryisabelle correctiontoremind2comparativeeffectivenessoftafasitamabpluslenalidomideversuspolatuzumabvedotinbendamustinerituximabpolabrcarttherapiesandlenalidomiderituximabr2basedonrealworlddatainpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT greilrichard correctiontoremind2comparativeeffectivenessoftafasitamabpluslenalidomideversuspolatuzumabvedotinbendamustinerituximabpolabrcarttherapiesandlenalidomiderituximabr2basedonrealworlddatainpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT kumatthew correctiontoremind2comparativeeffectivenessoftafasitamabpluslenalidomideversuspolatuzumabvedotinbendamustinerituximabpolabrcarttherapiesandlenalidomiderituximabr2basedonrealworlddatainpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT marksreinhard correctiontoremind2comparativeeffectivenessoftafasitamabpluslenalidomideversuspolatuzumabvedotinbendamustinerituximabpolabrcarttherapiesandlenalidomiderituximabr2basedonrealworlddatainpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT kimkibum correctiontoremind2comparativeeffectivenessoftafasitamabpluslenalidomideversuspolatuzumabvedotinbendamustinerituximabpolabrcarttherapiesandlenalidomiderituximabr2basedonrealworlddatainpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT zinzanipierluigi correctiontoremind2comparativeeffectivenessoftafasitamabpluslenalidomideversuspolatuzumabvedotinbendamustinerituximabpolabrcarttherapiesandlenalidomiderituximabr2basedonrealworlddatainpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT trotmanjudith correctiontoremind2comparativeeffectivenessoftafasitamabpluslenalidomideversuspolatuzumabvedotinbendamustinerituximabpolabrcarttherapiesandlenalidomiderituximabr2basedonrealworlddatainpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT sabatellilorenzo correctiontoremind2comparativeeffectivenessoftafasitamabpluslenalidomideversuspolatuzumabvedotinbendamustinerituximabpolabrcarttherapiesandlenalidomiderituximabr2basedonrealworlddatainpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT waltlevae correctiontoremind2comparativeeffectivenessoftafasitamabpluslenalidomideversuspolatuzumabvedotinbendamustinerituximabpolabrcarttherapiesandlenalidomiderituximabr2basedonrealworlddatainpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT winderlichmark correctiontoremind2comparativeeffectivenessoftafasitamabpluslenalidomideversuspolatuzumabvedotinbendamustinerituximabpolabrcarttherapiesandlenalidomiderituximabr2basedonrealworlddatainpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT sporchiaandrea correctiontoremind2comparativeeffectivenessoftafasitamabpluslenalidomideversuspolatuzumabvedotinbendamustinerituximabpolabrcarttherapiesandlenalidomiderituximabr2basedonrealworlddatainpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT kurukulasuriyanuwanc correctiontoremind2comparativeeffectivenessoftafasitamabpluslenalidomideversuspolatuzumabvedotinbendamustinerituximabpolabrcarttherapiesandlenalidomiderituximabr2basedonrealworlddatainpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT cordobaraul correctiontoremind2comparativeeffectivenessoftafasitamabpluslenalidomideversuspolatuzumabvedotinbendamustinerituximabpolabrcarttherapiesandlenalidomiderituximabr2basedonrealworlddatainpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT hessgeorg correctiontoremind2comparativeeffectivenessoftafasitamabpluslenalidomideversuspolatuzumabvedotinbendamustinerituximabpolabrcarttherapiesandlenalidomiderituximabr2basedonrealworlddatainpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT sallesgilles correctiontoremind2comparativeeffectivenessoftafasitamabpluslenalidomideversuspolatuzumabvedotinbendamustinerituximabpolabrcarttherapiesandlenalidomiderituximabr2basedonrealworlddatainpatientswithrelapsedrefractorydiffuselargebcelllymphoma |